Andy Ryan
YOU?
Author Swipe
View article: Estimating the Opportunity for Early Detection of Ovarian Cancer Using Individual-Patient Data from a Large Randomized Controlled Trial
Estimating the Opportunity for Early Detection of Ovarian Cancer Using Individual-Patient Data from a Large Randomized Controlled Trial Open
Background: The UK Collaborative Trial of Ovarian Cancer Screening did not detect a reduction in ovarian cancer mortality with either multimodal screening (MMS) or transvaginal ultrasound screening (USS) compared with no screening. The tri…
View article: Plasma cell‐free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case‐control study and an ovarian cancer screening trial
Plasma cell‐free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case‐control study and an ovarian cancer screening trial Open
Analysis of cell‐free DNA methylation (cfDNAme), alone or combined with CA125, could help to detect ovarian cancers earlier and may reduce mortality. We assessed cfDNAme in regions of ZNF154, C2CD4D and WNT6 via targeted bisulfite sequenci…
View article: Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials
Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials Open
Randomised controlled trials are challenging to deliver. There is a constant need to review and refine recruitment and implementation strategies if they are to be completed on time and within budget. We present the strategies adopted in th…
View article: 231P Trastuzumab deruxtecan for the treatment of metastatic breast cancer in the UK: Real-world data
231P Trastuzumab deruxtecan for the treatment of metastatic breast cancer in the UK: Real-world data Open
The treatment of human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (mBC) has changed dramatically with the introduction of several new anti-HER2 agents. In 2021, Trastuzumab Deruxtecan (TDXd) was approved i…
View article: Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial
Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial Open
Background Ovarian and tubal cancers are lethal gynaecological cancers, with over 50% of the patients diagnosed at advanced stage. Trial design Randomised controlled trial involving 27 primary care trusts adjacent to 13 trial centres based…
View article: Supplementary Tables from Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer
Supplementary Tables from Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer Open
Tables 1-4
View article: Data from Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer
Data from Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer Open
Early detection of ovarian cancer has the potential to impact mortality. A multimodal screening strategy where rising CA125 values over time, analyzed with the risk of ovarian cancer algorithm (ROCA), triggers transvaginal sonography and p…
View article: Supplementary Figures from Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer
Supplementary Figures from Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer Open
Figures 1-3
View article: Data from Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer
Data from Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer Open
Early detection of ovarian cancer has the potential to impact mortality. A multimodal screening strategy where rising CA125 values over time, analyzed with the risk of ovarian cancer algorithm (ROCA), triggers transvaginal sonography and p…
View article: Supplementary Figures from Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer
Supplementary Figures from Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer Open
Figures 1-3
View article: Supplementary Tables from Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer
Supplementary Tables from Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer Open
Tables 1-4
View article: Data from KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib
Data from KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib Open
Purpose: VEGF pathway inhibitors have been investigated as therapeutic agents in the treatment of non–small cell lung cancer (NSCLC) because of its central role in angiogenesis. These agents have improved survival in patients with advanced…
View article: Data from Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer
Data from Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer Open
Purpose: The TP53 tumor-suppressor gene is mutated in >95% of high-grade serous ovarian cancers. Detecting an autologous antibody response to TP53 that might improve early detection.Experimental Design: An immunoassay was developed to meas…
View article: Data from KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib
Data from KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib Open
Purpose: VEGF pathway inhibitors have been investigated as therapeutic agents in the treatment of non–small cell lung cancer (NSCLC) because of its central role in angiogenesis. These agents have improved survival in patients with advanced…
View article: Supplemental Figure 1 from KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib
Supplemental Figure 1 from KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib Open
Supplemental Figure 1. (A) Calu-1 cells were treated with VEGF (50 ng/ml) for 15 minutes and phospho-p38 levels were evaluated by Western blotting. VEGF treatment resulted in activation of p38, and this was blocked with the addition of VEG…
View article: Supplemental Table 1 from KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib
Supplemental Table 1 from KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib Open
In the TCGA NSCLC dataset there was a significantly greater prevalence of p53 mutations in patients with KDR CNG compared to KDR CNG negative patients (p = 0.001).
View article: Supplemental Figure 1 from KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib
Supplemental Figure 1 from KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib Open
Supplemental Figure 1. (A) Calu-1 cells were treated with VEGF (50 ng/ml) for 15 minutes and phospho-p38 levels were evaluated by Western blotting. VEGF treatment resulted in activation of p38, and this was blocked with the addition of VEG…
View article: Supplementary Table 1 from Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population
Supplementary Table 1 from Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population Open
MMT / PEB values in training and validation of the algorithms based on the primary analysis
View article: Supplemental Figure 2 from KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib
Supplemental Figure 2 from KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib Open
Supplemental Figure 2. VEGFR TKIs inhibit the migration of NSCLC cells with KDR CNGs.
View article: Data from Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population
Data from Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population Open
Purpose: In the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), women in the multimodal (MMS) arm had a serum CA125 test (first-line), with those at increased risk, having repeat CA125/ultrasound (second-line test…
View article: Data from Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer
Data from Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer Open
Purpose: The TP53 tumor-suppressor gene is mutated in >95% of high-grade serous ovarian cancers. Detecting an autologous antibody response to TP53 that might improve early detection.Experimental Design: An immunoassay was developed to meas…
View article: Supplemental Figure 2 from KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib
Supplemental Figure 2 from KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib Open
Supplemental Figure 2. VEGFR TKIs inhibit the migration of NSCLC cells with KDR CNGs.
View article: Supplementary Table 1 from Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population
Supplementary Table 1 from Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population Open
MMT / PEB values in training and validation of the algorithms based on the primary analysis
View article: Figures S1-S6; Table S1-S5 from Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer
Figures S1-S6; Table S1-S5 from Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer Open
Supplementary figures, tables and materials & methods Supplementary Figure 1. Schematic presentation of steps in immunoassay development, validation and studies for screening TP53 autoantibody in human serum samples. Supplementary Figure 2…
View article: Supplementary figure legend from KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib
Supplementary figure legend from KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib Open
Supplementary figure legend
View article: Supplemental Table 1 from KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib
Supplemental Table 1 from KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib Open
In the TCGA NSCLC dataset there was a significantly greater prevalence of p53 mutations in patients with KDR CNG compared to KDR CNG negative patients (p = 0.001).